Newborn screening quality assurance

Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease

Volumn , Issue , 2009, Pages

  Hannon, W Harry ^a   Henderson, L Omar ^a   Bell, Carol J ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

DBSs; Genetic testing; Newborn screening programs; Nsqap; Public health; Quality control

Indexed keywords

EID: 84940016102     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195128307.003.0013     Document Type: Chapter

References (18)

1. Guthrie R. The origin of newborn screening. Screening 1992;1:5-15.
2. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
3. MacCready RA. Phenylketonuria in screening programs. N Engl J Med 1963: 269:52-56.
4. National Academy of Sciences. Genetic screening: programs, principles, and research. Washington, DC: National Academy Press, 1975, p. 91.
5. Hiller EH, Landenburger G, Natowicz MR. Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States. Am J Public Health 1997;87:1280-1288.
6. Newborn Screening Committee, Council of Regional Networks for Genetic Services (CORN). National Newborn Screening Report-1995. Atlanta (in press).
7. Slazyk WE, Hannon WH. Quality assurance in the newborn screening laboratory. In:Therrell BL Jr (ed). Laboratory methods for neonatal screening. Washington, DC:American Public Health Association, 1993, pp. 23-46.
8. Hannon WH, Boyle J, Davin B, et al. Blood collection on filter paper for neonatal screening programs (3rd ed): approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997. NCCLS Document LA4-A3.
9. Slazyk WE, Phillips DL, Therrell BL Jr, Hannon WH. The effect of lot-to-lot variability in filter paper on the quantification of thyroxin, thyrotropin and phenylalanine in dried-blood specimens. Clin Chem 1988;34:53-58.
10. Arends J. Neonatal screening using dried blood spotted on filter paper:methodological factors which contribute to imprecision. In: Therrell BL Jr (ed). Advances in neonatal screening. Proceedings of the 6th International Neonatal Screening Symposium; 1986 Nov 16-19; Austin, TX. Amsterdam: Elsevier Science Publishers, 1987, pp. 549-550.
11. Therrell BL Jr, Panny SR, Davidson A, et al. U.S. newborn screening system guidelines: statement of the Council of Regional Networks for Genetic Services. Screening 1992;1:135-147.
12. Ziadeh R, Hoffman EP, Finegold DN, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995;37:675-678.
13. Federal register. 1992, Feb 28;57(40):7150-7185.
14. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development-proceedings of a 1997 workshop. MMWR 1997;46 (No. RR-16):13-14.
15. McCabe ERB. Utility of PCR for DNA analysis from dried blood spots on filter paper blotters. PCR Methods Appl 1991;1:99-106.
16. Therrell BL Jr, Hannon WH, Pass KA, et al. Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Mol Med 1996;57:116-124.
17. McEwen JE, Reilly PR. Stored Guthrie cards as DNA banks. Am J Hum Genet 1994;55:196-200.
18. Andrews LB (ed). Legal liability and quality assurance in newborn screening. Chicago:American Bar Foundation, 1985, pp. 29-73.